Curated summaries of published, peer-reviewed research on research peptides. All articles link directly to their original source on PubMed, PMC, or the publishing journal.
A comprehensive synthesis of 544 articles (1993–2024) from PubMed, Cochrane, and Embase. Of 36 included studies, researchers found BPC-157 enhances growth hormone receptor expression, promotes angiogenesis via VEGFR2, and reduces inflammatory cytokines. In a human retrospective study, 7 of 12 patients with chronic knee pain reported relief exceeding 6 months following a single intra-articular injection.
544 articles identified; 36 studies included
Improved outcomes in tendon, ligament, muscle & bone injury models
58% human clinical response rate in knee pain study
Favourable toxicology profile across all reviewed studies
Evaluates molecular mechanisms, therapeutic potential, and safety concerns of BPC-157 in musculoskeletal healing contexts. Reviews preclinical and limited clinical evidence, noting a pilot IV safety study in two adults up to 20mg showed no adverse events, with plasma clearance within 24 hours.
Curr Rev Musculoskelet Med · 2025
PMC12446177
Comprehensive open-access review covering BPC-157, TB-500, GHK-Cu, Ipamorelin, and CJC-1295. Examines PI3K/Akt, mTOR, MAPK, TGF-β and AMPK signalling pathways. Documents how GHK-Cu stimulates dermal fibroblast proliferation and regulates matrix metalloproteinases in soft-tissue regeneration applications.
JAAOS · Open Access · 2025
PMC12753158
Landmark genomic review demonstrating GHK-Cu modulates expression of over 1,500 genes. Clinical data shows topical GHK-Cu improved collagen production in 70% of subjects after 12 weeks — outperforming both vitamin C cream (50%) and retinoic acid (40%) in the same cohort. Documents stimulation of blood vessel growth, nerve outgrowth, and dermal fibroblast support.
Int J Mol Sci · PMC · 2018
PMC6073405
PMC-indexed review of placebo-controlled clinical studies in women aged ~50. Facial cream containing GHK-Cu applied for 12 weeks to 71 women with photoaging increased skin density, thickness, and reduced fine lines. Documents GHK-Cu's capacity to restore fibroblast function damaged by radiation therapy, and its activation of both TGF-beta and integrin beta 1 pathways.
Biomolecules · PMC · 2019
PMC4508379
Systematic review covering studies published 2016–2025. Documents GHK-based formulations — including nanoparticle conjugates, hydrogels, and clinical derivatives TriHex and TriHex 2.0 — enhancing fibroblast migration, ECM remodelling, collagen and elastin synthesis, and wound closure with antimicrobial activity.
Med Sci Monit · 2025
medsci.org/v22p4175
Preprint reviewing AOD-9604, BPC-157, CJC-1295, Follistatin-344, GHK-Cu, Ipamorelin, and TB-500. Includes Google Trends data showing significant search volume increase from 2024 onward. Presents pharmacological mechanisms, regulatory status, and safety profiles for each compound, noting BPC-157 and Tirzepatide searches have considerably increased since 2024.
Preprints.org · 2025
Preprint (peer review pending)
Commentary responding to a landmark 2024 review of over 130 BPC-157 references spanning 30 years of research. Discusses the peptide's unique stability in gastric juice (due to four proline residues resisting trypsin and chymotrypsin), its pleiotropic gastrointestinal protective effects, and raises key questions regarding clinical combination therapies.
Inflammopharmacology · Springer · 2025
DOI: 10.1007/s10787-025-01882-z
2025 BioImpacts study investigating the skin permeability of GHK and its derivatives GHK-Cu and Pal-GHK. Confirms GHK is a hydrophilic peptide with challenging transdermal delivery. Reviews metal complexation and palmitoylation as permeability enhancement strategies, and identifies cell-penetrating peptides and microneedle pretreatment as promising delivery approaches for clinical applications.
BioImpacts · Open Access · 2025
bi-30071
Phase 2 clinical research (LY3437943) published in NEJM 2023 demonstrated significant metabolic parameter changes in study participants. Retatrutide's triple agonism at GIP, GLP-1, and glucagon receptors differentiates it from dual agonists in terms of receptor binding profile. Research continues into its comparative pharmacokinetics and receptor selectivity versus Tirzepatide.
N Engl J Med · 2023
DOI: 10.1056/NEJMoa2301972
Research Reference Disclaimer: All articles linked on this page are published in peer-reviewed journals or publicly accessible scientific databases (PubMed, PMC, Springer, NEJM). Kuro Labs curates these references for informational purposes only. These summaries do not constitute medical advice, clinical recommendations, or endorsement of any particular use. All compounds described are sold strictly for in vitro laboratory research by qualified researchers.